Resonance Health

Burswood, Western Australia, Australia  All Australia companies → — Founded 1987
Imaging AI Specialist Specialty-Focused AI
Public

Products

FerriSmart Analysis System
Resonance Health
Gastroenterology AI
FerriSmart Analysis System is an AI-driven, FDA-cleared software that provides automated, real-time quantification of liver iron concentration from MRI images, aiding in the diagnosis and management of iron overload conditions.
HepaFatSmart
Resonance Health
Endocrinology & Metabolic AI
HepaFatSmart is an FDA-cleared, AI-powered Software-as-a-Medical Device (SaMD) that provides automated, multi-metric assessment of liver fat from MRI scans, including VLFF, PDFF, and steatosis grade.

See all 2 products →

About Resonance Health

Resonance Health is an Australian MedTech company specializing in the development and commercialization of non-invasive medical imaging software and services. Their products are designed for quantitative analysis of radiological images in a regulated and quality-controlled environment. These solutions are utilized by clinicians globally for the diagnosis and management of various human diseases, and by pharmaceutical companies for clinical trials.

The company’s portfolio includes post-MRI analysis products, with a strong focus on liver and heart conditions. Their flagship product, FerriScan®, provides a highly precise evaluation of Liver Iron Concentration (LIC) using R2-MRI technology, crucial for managing conditions like Thalassaemia and other iron overload disorders. They also offer HepaFatScan® for evaluating liver fat concentration, which has been validated against liver biopsy. Resonance Health has expanded its offerings with AI-powered products like FerriSmart® for automated LIC evaluation, HepaFatSmart® for multi-metric liver fat assessment, and LiverSmart®, which combines both into a single report. These products are classified as Software as a Medical Device (SaMD) and hold regulatory clearances such as FDA (USA) and CE mark (EU MDR 2017/745).

Resonance Health also has an active research and development program, including current research in liver fibrosis and inflammation, aiming to develop non-invasive MRI-based biomarkers. They also provide clinical trial services and have established strategic alliances to make their MRI analysis endpoints available through global clinical trial networks.

Focus Areas

non-invasive medical imaging analysis liver iron concentration liver fat assessment cardiac iron assessment clinical trials software-as-a-medical-device (SaMD) artificial intelligence in medical imaging

Business Intelligence

Technologycloud-based user portal, AI-powered engine, Dynamika AI-enabled cloud imaging platform (via IAG partnership)

What Physicians Need to Know

Non-invasive Medical Imaging Analysis
Resonance Health specializes in non-invasive MRI-based solutions for quantifying liver iron concentration (FerriScan®, FerriSmart®), liver fat (HepaFatScan®, HepaFatSmart®), and cardiac iron (Cardiac T2*). They also have an AI-powered solution for combined liver iron and fat assessment called LiverSmart®.
Liver Iron Concentration (LIC)
FerriScan® is a non-invasive MRI-based solution for quantifying liver iron concentration across the full clinical spectrum and is considered a gold standard. FerriSmart® is an AI-powered solution for real-time quantification of LIC through MRI scanning, maintaining the high standards of FerriScan® and compatible with a wide range of MRI scanners.
Liver Fat Assessment
HepaFatScan® is a non-invasive MRI-based solution for measuring the volumetric fraction of fat in liver tissue, comparable to volumetric biopsy fat fraction measurement. HepaFatSmart® is an automated, AI-powered multi-metric assessment of liver fat.
Cardiac Iron Assessment
Resonance Health offers Cardiac T2* for assessing iron in the heart using MRI technology, which has regulatory approval for routine clinical practice and is frequently used to monitor cardiac iron levels in patients with thalassemia.
Clinical Trials
Resonance Health partners with biopharmaceutical companies and CROs to conduct quality-assured clinical trials, offering services with the benefit of the Australian government subsidy program. They provide post-imaging software for standardized analysis across multiple clinical trial sites. Their products and services are utilized in clinical trials for various therapeutic areas, including metabolic disease, liver-related disease, and iron overload disorders.
Software-as-a-Medical-Device (SaMD)
Resonance Health's products are classified as SaMD and have regulatory clearances from the FDA (USA), CE mark (EU MDR 2017/745), and ARTG (Australia). Their SaMD services are delivered through AI-enabled cloud imaging platforms for multi-modality clinical trials.
Artificial Intelligence in Medical Imaging
Resonance Health has expanded its portfolio by developing AI-powered products that use specially trained convolutional neural networks to analyze MRI and other medical images. FerriSmart®, HepaFatSmart®, and LiverSmart® are examples of their AI-powered solutions for liver iron and fat assessment.
Physician Tip

Resonance Health provides non-invasive, accurate, and accessible MRI-based solutions for quantifying liver iron concentration and liver fat, which can enhance diagnosis, monitoring, and management of iron-related disorders and fatty liver disease. Their highly visual, color-coded reports offer clear and easy-to-interpret results, supporting clinical decision-making. The AI-powered solutions like FerriSmart® and HepaFatSmart® provide real-time data for instant diagnostic and treatment decisions. LiverSmart® combines both liver iron and fat assessment into a single MRI session and consolidated report, offering a more comprehensive and convenient evaluation. Their products are MRI agnostic, ensuring standardized results across various scanners, and require no capital equipment purchase by radiology facilities.

Resonance Health's SaMD services are designed to be integrated into global clinical trial strategies and can be delivered through AI-enabled cloud imaging platforms. They also partner with radiology image-processing firms to include their AI tool's liver iron concentration data in reports. Their Patient Center platform is a web-based data management system used by healthcare providers, researchers, governments, and physicians to manage patient data, offering features like secure medical records, physician consult systems, and appointment scheduling.

Products by Resonance Health

2 products in the directory

FerriSmart Analysis System
Resonance Health
Gastroenterology AI
FerriSmart Analysis System is an AI-driven, FDA-cleared software that provides automated, real-time quantification of liver iron concentration from MRI images, aiding in the diagnosis and management of iron overload conditions.
HepaFatSmart
Resonance Health
Endocrinology & Metabolic AI
HepaFatSmart is an FDA-cleared, AI-powered Software-as-a-Medical Device (SaMD) that provides automated, multi-metric assessment of liver fat from MRI scans, including VLFF, PDFF, and steatosis grade.

What the Web Says

Resonance Health appears to be a company with a mixed online presence, with some positive product reviews for specific health devices and apps, but also some confusion and skepticism surrounding the broader concept of "bioresonance" therapy. The company's medical imaging services, particularly FerriScan, receive positive mentions in a professional context. Employer reviews are scarce and often conflated with other companies containing "Resonance" in their name.

Overall: Mixed

Strengths

  • Compact and easy-to-use devices for sleep, pain management, and wellness (Resona Health Vibe).
  • Responsive customer service for product assistance and support.
  • App (Resonance App) reported to help with hair loss and skin issues.
  • FerriScan R2-MRI device has FDA approval and is used in conjunction with pharmaceutical therapy.
  • Positive financial performance noted in a Reddit discussion about RHT (Resonance Health Ltd on ASX).
  • Offers specialized liver and heart iron analysis products and phantoms for MRI scanner verification and quality assurance.

Limitations

  • Lack of clear online guidance for some products.
  • Some users felt products did not deliver noticeable health results.
  • Occasional difficulties with device durability, hardware functionality, or program operation.
  • The broader concept of "bioresonance" therapy is viewed as a scam by some on Reddit, with concerns about its efficacy and potential to deter individuals from seeking conventional medical treatment.
  • Difficulty in finding specific employer reviews for "Resonance Health" due to similar company names.
  • Limited reviews on major IT review platforms like G2, Glassdoor, and Capterra directly for Resonance Health's core offerings.

Based on reviews from: Junip, Trustpilot, Resonance App Reviews, Reddit, AuntMinnie

Last updated: 2026-10-20

Videos

News, demos, and interviews about Resonance Health.

Loading videos...

Videos load interactively. If none appear, search YouTube for Resonance Health →

View all on YouTube

Press & Coverage

Kalkine Media
Resonance Health (ASX:RHT): FY26 Profit Return, Clinical Trials and Imaging Software
Resonance Health reported higher revenue and a return to statutory profitability in its FY26 annual results, published in August 2026. The company's activities span healthcare technology, contract research, and trial-site operations, with an operational priority to replace revenue from a major clinical trial.
2026-10
Kalkine
Resonance Health to Release MRI Liver Fibrosis EPoC Clinical Trial Preliminary Results on 28 October 2026
Resonance Health is set to release the preliminary results of its MRI Liver Fibrosis EPoC Clinical Trial on October 28, 2026. This trial is a significant step towards validating a new non-invasive MRI-based medical device for liver fibrosis detection.
2026-10
Small Caps
Resonance Health Improves Cash Position as Clinical Trial Pipeline Expands
Resonance Health completed recruitment for its 'Non-Invasive MRI Liver Fibrosis' device extended-proof-of-concept trial in July 2026, with analysis underway. A favorable outcome could lead to regulatory planning and potential use of the product as an investigational endpoint in clinical trials.
2026-07
Small Caps
Resonance Health Partners with UK CRO to Include SaMD Services in Global Clinical Trials
In September 2026, Resonance Health entered a 24-month strategic alliance with UK-based CRO Image Analysis to integrate its quantitative MRI body composition endpoints into global clinical trials, particularly for obesity and metabolic diseases. This partnership will leverage Resonance's Software-as-Medical-Device (SaMD) services through Image's Dynamika AI-enabled cloud imaging platform.
2026-09
AFR
ASX Announcement – 10 June 2025 - InvestorHub Launch
Resonance Health launched 'InvestorHub' in June 2025, a new platform for investor engagement providing ASX announcements, shareholder news, and key updates. The company is focusing on growth in clinical trial management, Software-as-a-Medical Device (SaMD) image analysis, and clinical trial site services.
2025-06
Listcorp
Resonance Contracted by Major Global Pharma
In November 2024, Resonance Health secured a $13.8 million, 24-month agreement with Sun Pharmaceutical for clinical trial services. This contract includes clinical research organization, trial site, and imaging analysis services for a new drug compound.
2024-11
Resonance Health Investor Hub
Board Changes
Dr. Martin Blake announced his retirement as Chair and Non-Executive Director of Resonance Health, effective November 13, 2025, after 18 years of service. Mr. Aaron Brinkworth will transition into the role of Chair following the AGM.
2025-10
Western Australian Government
AusBiotech 2024: Resonance Health
Resonance Health participated in AusBiotech 2024, showcasing its imaging CRO and clinical site services. The company provides imaging CRO services for global clinical trials using its regulatory-cleared MRI Software as a Medical Device (SaMD) products and investigational-use only products.
2024-10

Frequently Asked Questions

Resonance Health offers several non-invasive MRI-based solutions. For liver iron concentration, they provide FerriScan® and the AI-powered FerriSmart®. For liver fat assessment, they offer HepaFatScan® and HepaFatSmart®. Additionally, they provide Cardiac T2* for assessing cardiac iron.
Resonance Health's products are classified as Software as a Medical Device (SaMD) and have received regulatory clearances from various bodies, including the FDA (USA), CE mark (EU MDR 2017/745), and ARTG (Australia).
Resonance Health utilizes AI in several of its products to automate and enhance analysis. FerriSmart® and HepaFatSmart® are AI-powered solutions that use specially trained convolutional neural networks to analyze MRI images for liver iron concentration and multi-metric liver fat evaluation, respectively. LiverSmart® combines these into a single report.
Yes, Resonance Health works with biopharmaceutical companies and CROs to conduct quality-assured clinical trials. They offer imaging CRO services, trial site services, and imaging analysis, including their regulatory-cleared SaMD products for standardized analysis across multiple sites.
Resonance Health provides support through their team for general inquiries and clinical trial information. They have also established partnerships, such as with 3DR Labs to expand FerriSmart® availability in the US, and a strategic alliance with UK CRO Image Analysis to integrate their SaMD services into global clinical trials.
Resonance Health is an Australian MedTech company. The company has shown positive financial indicators, including returning to full-year profitability in FY26 with a net profit after tax of AUD 1.5 million and positive operating cash flow. They have a diversified business model and a strong contracted revenue base in clinical trials, supporting sustained growth.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]

CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) technologies for capsule endoscopy solutions. Their primary goal is to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. [7] Their flagship product, the CapsoCam Plus system, is a single-use capsule endoscope equipped with four cameras, providing […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.